vs
Side-by-side financial comparison of MEDIFAST INC (MED) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $75.1M, roughly 1.2× MEDIFAST INC). On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs -36.9%). Vericel Corp produced more free cash flow last quarter ($12.8M vs $-6.6M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs -34.4%).
Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
MED vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $75.1M | $92.9M |
| Net Profit | — | $23.2M |
| Gross Margin | 69.4% | 78.7% |
| Operating Margin | -10.4% | 24.1% |
| Net Margin | — | 25.0% |
| Revenue YoY | -36.9% | 23.3% |
| Net Profit YoY | — | 17.3% |
| EPS (diluted) | $-1.64 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.1M | $92.9M | ||
| Q3 25 | $89.4M | $67.5M | ||
| Q2 25 | $105.6M | $63.2M | ||
| Q1 25 | $115.7M | $52.6M | ||
| Q4 24 | $119.0M | $75.4M | ||
| Q3 24 | $140.2M | $57.9M | ||
| Q2 24 | $168.6M | $52.7M | ||
| Q1 24 | $174.7M | $51.3M |
| Q4 25 | — | $23.2M | ||
| Q3 25 | $-2.3M | $5.1M | ||
| Q2 25 | $2.5M | $-553.0K | ||
| Q1 25 | $-772.0K | $-11.2M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | $1.1M | $-901.0K | ||
| Q2 24 | $-8.2M | $-4.7M | ||
| Q1 24 | $8.3M | $-3.9M |
| Q4 25 | 69.4% | 78.7% | ||
| Q3 25 | 69.5% | 73.5% | ||
| Q2 25 | 72.6% | 73.7% | ||
| Q1 25 | 72.8% | 69.0% | ||
| Q4 24 | 74.1% | 77.6% | ||
| Q3 24 | 75.4% | 71.9% | ||
| Q2 24 | 73.2% | 69.5% | ||
| Q1 24 | 72.8% | 68.9% |
| Q4 25 | -10.4% | 24.1% | ||
| Q3 25 | -4.6% | 5.1% | ||
| Q2 25 | -1.0% | -3.2% | ||
| Q1 25 | -1.1% | -24.3% | ||
| Q4 24 | 0.6% | 24.5% | ||
| Q3 24 | 1.5% | -4.3% | ||
| Q2 24 | -4.7% | -11.5% | ||
| Q1 24 | 4.5% | -10.7% |
| Q4 25 | — | 25.0% | ||
| Q3 25 | -2.5% | 7.5% | ||
| Q2 25 | 2.3% | -0.9% | ||
| Q1 25 | -0.7% | -21.4% | ||
| Q4 24 | — | 26.3% | ||
| Q3 24 | 0.8% | -1.6% | ||
| Q2 24 | -4.8% | -8.9% | ||
| Q1 24 | 4.8% | -7.5% |
| Q4 25 | $-1.64 | $0.46 | ||
| Q3 25 | $-0.21 | $0.10 | ||
| Q2 25 | $0.22 | $-0.01 | ||
| Q1 25 | $-0.07 | $-0.23 | ||
| Q4 24 | $0.08 | $0.40 | ||
| Q3 24 | $0.10 | $-0.02 | ||
| Q2 24 | $-0.75 | $-0.10 | ||
| Q1 24 | $0.76 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.3M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $198.9M | $354.6M |
| Total Assets | $248.0M | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.3M | $137.5M | ||
| Q3 25 | $173.5M | $135.4M | ||
| Q2 25 | $162.7M | $116.9M | ||
| Q1 25 | $164.6M | $112.9M | ||
| Q4 24 | $162.3M | $116.2M | ||
| Q3 24 | $170.0M | $101.7M | ||
| Q2 24 | $163.5M | $102.5M | ||
| Q1 24 | $156.4M | $110.6M |
| Q4 25 | $198.9M | $354.6M | ||
| Q3 25 | $214.7M | $321.9M | ||
| Q2 25 | $216.0M | $306.8M | ||
| Q1 25 | $211.0M | $295.5M | ||
| Q4 24 | $210.1M | $292.0M | ||
| Q3 24 | $207.3M | $257.5M | ||
| Q2 24 | $205.3M | $243.0M | ||
| Q1 24 | $211.0M | $233.9M |
| Q4 25 | $248.0M | $488.0M | ||
| Q3 25 | $268.2M | $453.3M | ||
| Q2 25 | $269.3M | $435.6M | ||
| Q1 25 | $280.0M | $424.6M | ||
| Q4 24 | $284.2M | $432.7M | ||
| Q3 24 | $291.2M | $390.4M | ||
| Q2 24 | $293.5M | $376.8M | ||
| Q1 24 | $302.8M | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.3M | $15.0M |
| Free Cash FlowOCF − Capex | $-6.6M | $12.8M |
| FCF MarginFCF / Revenue | -8.8% | 13.8% |
| Capex IntensityCapex / Revenue | 1.8% | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $1.2M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.3M | $15.0M | ||
| Q3 25 | $12.1M | $22.1M | ||
| Q2 25 | $-3.4M | $8.2M | ||
| Q1 25 | $3.4M | $6.6M | ||
| Q4 24 | $-4.9M | $22.2M | ||
| Q3 24 | $9.1M | $10.2M | ||
| Q2 24 | $13.1M | $18.5M | ||
| Q1 24 | $7.3M | $7.2M |
| Q4 25 | $-6.6M | $12.8M | ||
| Q3 25 | $10.8M | $19.5M | ||
| Q2 25 | $-4.8M | $81.0K | ||
| Q1 25 | $1.9M | $-7.6M | ||
| Q4 24 | $-7.2M | $8.5M | ||
| Q3 24 | $7.7M | $-9.2M | ||
| Q2 24 | $11.1M | $1.8M | ||
| Q1 24 | $5.4M | $-6.8M |
| Q4 25 | -8.8% | 13.8% | ||
| Q3 25 | 12.0% | 28.8% | ||
| Q2 25 | -4.5% | 0.1% | ||
| Q1 25 | 1.6% | -14.5% | ||
| Q4 24 | -6.1% | 11.2% | ||
| Q3 24 | 5.5% | -15.9% | ||
| Q2 24 | 6.6% | 3.4% | ||
| Q1 24 | 3.1% | -13.3% |
| Q4 25 | 1.8% | 2.4% | ||
| Q3 25 | 1.5% | 3.9% | ||
| Q2 25 | 1.3% | 12.9% | ||
| Q1 25 | 1.3% | 27.0% | ||
| Q4 24 | 1.9% | 18.3% | ||
| Q3 24 | 1.0% | 33.5% | ||
| Q2 24 | 1.1% | 31.8% | ||
| Q1 24 | 1.1% | 27.3% |
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 4.35× | ||
| Q2 25 | -1.36× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | 8.04× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MED
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
